What's Happening?
Made Scientific, a cell therapy contract development and manufacturing organization, has partnered with Syenex, a synthetic biology company, to improve the scalability and efficiency of engineered T cell therapies. The collaboration will utilize Syenex's bioengineering systems, UltraCell™ and RapidCell™, to enhance gene delivery efficiency and reduce manufacturing timelines. This partnership aims to address the challenges of traditional T cell therapy manufacturing, such as scalability and cost, by offering up to a tenfold improvement in gene delivery efficiency. Initial studies have shown that the RapidCell™ system can streamline the manufacturing process and reduce costs significantly.
Why It's Important?
The partnership between Made Scientific and Syenex is significant for the biotechnology and pharmaceutical industries as it promises to make T cell therapies more accessible and affordable. By improving the efficiency and reducing the cost of manufacturing, this collaboration could accelerate the development and availability of life-saving therapies for patients. The advancements in gene delivery and manufacturing processes could also set new standards in the industry, potentially benefiting a wide range of therapeutic developers and ultimately improving patient outcomes.
What's Next?
The results from the initial proof-of-concept studies will be shared at a future forum, with plans to debut a customer-accessible manufacturing platform process incorporating the new technology by 2026. This development could lead to broader adoption of the improved manufacturing techniques across the industry, further enhancing the availability and effectiveness of T cell therapies.
